0.001
-0.01 (-95.83%)
| Previous Close | 0.012 |
| Open | 0.001 |
| Volume | 15,433 |
| Avg. Volume (3M) | 163,041 |
| Market Cap | 14,341 |
| Price / Book | 1.24 |
| 52 Weeks Range | |
| Earnings Date | 15 Nov 2024 - 18 Nov 2024 |
| Operating Margin (TTM) | -968.04% |
| Diluted EPS (TTM) | -3.54 |
| Quarterly Revenue Growth (YOY) | 150.30% |
| Current Ratio (MRQ) | 0.340 |
| Operating Cash Flow (TTM) | -51.00 M |
| Levered Free Cash Flow (TTM) | -29.10 M |
| Return on Assets (TTM) | -29.15% |
| Return on Equity (TTM) | -419.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | VBI Vaccines, Inc. (CDA) | - | - |
Stockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.0 |
| Average | 0.50 |
|
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.77% |
| % Held by Institutions | 3.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hantz Financial Services, Inc. | 30 Sep 2024 | 750 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |